Share
Phi Moments
Building Next-Gen Platforms for Preclinical Testing
Join us for the second episode of the Phi Moments podcast, "Building Next-Gen Platforms for Preclinical Testing," where host Rahul Ramchandra Ganar, Head - Life Sciences, Quantiphi dives into the innovations redefining drug discovery and development. We're joined by exceptional leaders, including Asif Hasan, Co-Founder, Quantiphi, Dr. Subhadra Dravida, Founder & CEO, Transcell Biologics, and Creator of the DART platform, and Dr. Sadanand Vodala, Industry Expert and Clinical Development Lead, Boehringer Ingelheim, moderated by Debraj Dasgupta. The discussion focuses on the critical shift toward faster, safer, and more human-relevant approaches in healthcare.
Explore how stem cell-based platforms, advanced AI, and non-animal methods like DART are transforming our understanding of disease mechanisms. The panelists tackle key industry challenges such as The Consistency Chasm, The Small Data Trap, and The Regulatory Black Box, and discuss how to build robust, explainable AI models for safety and toxicology decisions. Learn about the future of preclinical testing, from the emergence of Digital Twins to Inverse Design, and why the time for enterprise adoption of these ethical, efficient platforms is now.
Visit www.quantiphi.com for more information.
More episodes
View all episodes
1. Rethinking Preclinical Testing – The DART Advantage
22:40||Season 1, Ep. 1What if you could rethink preclinical testing — beyond animal models, beyond limitations? Join us for the first episode of our podcast, "Rethinking Preclinical Testing – The DART Advantage," featuring Dr. Subhadra Dravida, Founder & CEO, Transcell Biologics, as the guest speaker, in a powerful conversation with our host, Barinder Marhok, Global Head – Healthcare & Life Sciences, Quantiphi. Discover the Phi Moment – the breakthrough realization that led to DART, an AI-powered, stem cell-based platform that's rewriting the future of preclinical testing: faster, scalable, and more ethical.